Kalitabs

Potassium chloride, the active ingredient in Kalitabs, is an electrolyte supplement presented as an oral tablet for oral use. It helps restore normal serum potassium levels and corrects hypokalemia in patients who require potassium replenishment.

GNH USA supplies Kalitabs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kalitabs is an oral potassium chloride supplement used to address electrolyte disturbances that affect the cardiovascular and muscular systems.

- Hypokalemia: restores low serum potassium to normal ranges, supporting heart rhythm and muscle function. - Potassium deficiency: provides essential potassium ions to prevent weakness, fatigue, and arrhythmias. - Post‑operative potassium loss: corrects potassium depletion after surgery or intensive care treatment.

Kalitabs may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset after ingestion. - Abdominal discomfort: transient cramping or pain. - Diarrhea: loose stools occurring shortly after dosing. - Taste disturbance: metallic or salty taste in the mouth. - Vomiting: occasional emesis, especially with rapid intake. - Hyperkalemia (mild): slight elevation of serum potassium that resolves with dose adjustment.

Serious or Rare Side Effects: - Severe hyperkalemia: marked increase in serum potassium that can cause cardiac arrhythmia. - Cardiac arrest: life‑threatening rhythm disturbance linked to excessive potassium. - Anaphylactic reaction: rare allergic response with hives, swelling, or breathing difficulty. - Muscle weakness: pronounced loss of strength due to electrolyte imbalance. - Arrhythmias: irregular heartbeats that may require medical intervention. - Metabolic acidosis: uncommon disturbance of blood pH.

When prescribing Kalitabs, clinicians should consider several safety measures to minimize risk.

- Serum potassium monitoring: check levels before initiation and regularly during therapy. - Renal function assessment: adjust dose in patients with impaired kidney clearance. - Concomitant ACE inhibitor or ARB use: evaluate risk of additive potassium increase. - Existing hyperkalemia: avoid use if serum potassium is already elevated. - Cardiac evaluation: perform ECG if significant potassium shifts are expected. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Kalitabs can interact with other medications that influence potassium balance or cardiac electrophysiology.

Major Interactions (Avoid): - ACE inhibitors (e.g., enalapril): may cause dangerous hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): additive potassium increase. - ARBs (e.g., losartan): heightened risk of elevated serum potassium.

Moderate Interactions (Monitor Closely): - Digoxin: altered cardiac conduction when potassium levels fluctuate. - NSAIDs (e.g., ibuprofen): can reduce renal potassium excretion. - Lithium: potassium shifts may affect lithium toxicity. - Certain antibiotics (e.g., trimethoprim): may impair potassium handling.